Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001785530-24-000034
Filing Date
2024-11-07
Accepted
2024-11-07 09:09:08
Documents
65
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q howl-20240930.htm   iXBRL 10-Q 1483619
2 EX-31.1 a09302024ex311.htm EX-31.1 10338
3 EX-31.2 a09302024ex312.htm EX-31.2 10362
4 EX-32.1 a09302024ex321.htm EX-32.1 7048
  Complete submission text file 0001785530-24-000034.txt   5995135

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT howl-20240930.xsd EX-101.SCH 38076
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT howl-20240930_cal.xml EX-101.CAL 52633
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT howl-20240930_def.xml EX-101.DEF 205738
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT howl-20240930_lab.xml EX-101.LAB 465308
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT howl-20240930_pre.xml EX-101.PRE 356325
67 EXTRACTED XBRL INSTANCE DOCUMENT howl-20240930_htm.xml XML 658271
Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

IRS No.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40366 | Film No.: 241433464
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)